PepWay
An ingredient can appear in a serum and in advertising for an injectable compound. That does not make the products comparable. With GHK-Cu, purpose, formulation and route must remain visible so that discussions of evidence do not merge different contexts.
Cosmetic describes an intended product use
In the United States, FDA distinguishes cosmetics from medicines through intended use and claims. Cosmetics generally do not receive FDA premarket approval, apart from exceptions such as color additives. Consequently, “sold as a cosmetic” does not mean “approved medicine.” In Brazil, regularization requires checking the Anvisa context and specific product. Advertising with scientific symbols can imply a level of assessment that the actual document does not establish. Read what the document covers, rather than relying on a displayed badge or a broad statement about the business behind the product.
A route change changes the safety question
Application to the skin surface and injectable administration involve different exposures. Research or experience in one context cannot automatically transfer to another. FDA identifies limited human safety data for injectable GHK-Cu. That information is not guidance for preparing or using the compound. When a claim cites cosmetics to support systemic use, ask for research specifically evaluating the advertised route and purpose. If no such research is supplied, keep the gap explicit. A shared ingredient name does not bridge differences in exposure or establish that a safety finding applies across routes.
The label name does not describe the whole formulation
A cosmetic contains a collection of ingredients and formulation characteristics. Stated concentration, preservation, packaging and other components may influence tolerance and experience. An observation about one product cannot automatically be attributed to isolated GHK-Cu. Record the complete product name, entry date and other products used during the same period. With irritation, describe the signs and obtain appropriate guidance. Skin appearance or the absence of discomfort cannot establish safety for a different exposure. Preserving a list of ingredients can help a professional evaluate the actual product rather than an assumed single-ingredient explanation.
An example cosmetic routine record
A note could read: “identified cosmetic product; added Monday; also changed cleanser; noticed stinging on day three; photograph taken under usual lighting; question for assessment: which factors might be involved?” This is more informative than “GHK-Cu worked” or “did not work.” Photographs should use comparable conditions and remain private. They preserve observed appearance without measuring skin composition. When uncertain about a product, keep its ingredient list and the exact advertised purpose. A dated note also prevents accidentally attributing a change that began earlier to the newest item in the routine.
Careful vocabulary protects interpretation
Distinguish perceived improvement from clinical demonstration, ingredient from product, and regulatory listing from approval for an indication. “Cosmeceutical” and other marketing words do not resolve these differences. You can discuss an interest in skin care without turning it into validation of an experimental injectable compound. Ask about the concern you want to address and the specific product’s data. Personal organization should help describe the routine and recognize uncertainty while health assessment remains with qualified professionals. An accurate record can be useful even when it does not establish a cause or treatment effect.
Frequently asked questions
Does “cosmeceutical” mean an approved medicine?
No. The marketing term cannot replace a product’s regulatory status or establish a clinical indication.
Can a photograph confirm an ingredient’s effect?
Not by itself. Lighting, time, other products and skin changes can influence appearance. A photograph documents observations rather than proving causation.
Sources and references
Documents and research consulted for this article. Each source describes its own context; a reference does not confirm every use of a substance.
- FDA authority over cosmetics (opens in a new tab)FDA · Accessed October 14, 2026
- Potential safety risks of nominated bulk drug substances (opens in a new tab)FDA · Accessed October 14, 2026
- GHK-Cu and collagen synthesis in fibroblast cultures (1988) (opens in a new tab)FEBS Letters / PubMed · Accessed October 14, 2026
